{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.046","upperLimit":"1.000","value":"0.25"},{"groupId":"OG001","lowerLimit":"0.15","upperLimit":"0.92","value":"0.38"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"Kaplan-Meier estimate of the probability of progression-free survival at 1 year","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects with hematological malignancies with prior autologous transplant, \\>2 cycles of multiagent chemotherapy, or severely immune suppressive therapy in last 3 months, OR subjects with refractory leukemia and lymphoma in aplasia after induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy.\n\n* Cyclophosphamide 50 mg/Kg Day -6\n* Fludarabine 40mg/m2 Days -6 to -2\n* TBI 200 cGy Day -1\n\nImmune suppression: begin Day -3 cyclosporine and mycophenolate mofetil","id":"OG000","title":"Cyclophosphamide/Fludarabine/TBI"},{"description":"Subjects with hematological malignancies with prior autologous transplant \\>12 mos or \\<1 cycle of multiagent chemotherapy or NO immune suppressive chemotherapy in last 3 months.\n\n* Cyclophosphamide 50 mg/Kg Day -6\n* Fludarabine 40mg/m2 Days -6 to -2\n* TBI 200 cGy Day -1\n* Equine ATG 30mg/Kg Days -6 to -4\n\nImmune suppression: begin Day -3 cyclosporine and mycophenolate mofetil","id":"OG001","title":"Cyclophosphamide/Fludarabine/TBI/ATG"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year post transplant","title":"Probability of Progression-free Survival at 1 Year","type":"SECONDARY","unitOfMeasure":"progression free survival probability"}